Disease progression halted in rat model of Lou Gehrig's disease

Amyotrophic lateral sclerosis (ALS; also known as Lou Gehrig's disease) is an incurable adult neurodegenerative disorder that progresses to paralysis and death. Genetic mutations are the cause of disease in 5% of patients with ALS.

Of immense interest, Hongxia Zhou, Xu-Gang Xia, and colleagues, at Thomas Jefferson University, Philadelphia, now show that progressive neuron degeneration can be halted in a rat model of familial ALS linked to mutations in the gene that carries the instructions for making the protein TDP-43.

Progressive motor neuron degeneration was stopped when expression of the ALS-associated mutant human TDP-43 was switched off. If expression of the mutant protein was switched off before many had degenerated, the rats recovered function.

Conversely, if expression was switched off after most motor neurons had degenerated, functional recovery was minimal. These data indicate that mutant TDP-43 in motor neurons is sufficient to promote the onset and progression of ALS and that progression of motor neuron degeneration (and thereby progression of disease) is partially reversible in the rat model.


Explore further

Potential new drug target in Lou Gehrig's disease

More information: Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats J Clin Invest. doi:10.1172/JCI59130
Provided by Journal of Clinical Investigation
Citation: Disease progression halted in rat model of Lou Gehrig's disease (2011, December 12) retrieved 16 October 2019 from https://medicalxpress.com/news/2011-12-disease-halted-rat-lou-gehrig.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Dec 22, 2011
I have two personal friends with ALS. They would both love to stand in for one of those rats. When can they get a chance?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more